Top Pre-Market Stock Movers Friday June 26: FDA Approval, Earnings Beats, Energy Selloff

Friday, June 26, 2026 — The market is already in motion before the 9:30 a.m. ET opening bell. Major stocks are trading sharply higher and lower on pre-market catalysts ranging from better-than-expected earnings to FDA approvals and economic surprises. Understanding why stocks move before regular hours can help traders identify entry and exit points before the open.

Here are the most significant pre-market stock movers and the catalysts driving them.

Top Pre-Market Gainers: What's Driving the Biggest Moves Up

Pharmaceutical Stock Alpha (Ticker: PHARM) jumped 18.2% in pre-market trading to $87.44 on 4.3M shares, compared to its 30-day average volume of 2.1M. The catalyst: FDA approval of PHARM's Phase 3 trial for a Type 2 diabetes treatment came Thursday after market close. The drug showed a 34% improvement in HbA1c reduction versus the standard competitor therapy. This is PHARM's first blockbuster-potential drug in five years. The stock gapped up from its Thursday close of $73.88 and is now testing resistance at the $88 level.

Institutional investors are front-running the announcement before the regular session begins. Goldman Sachs initiated coverage with a "Buy" rating and a $105 price target Thursday evening, implying 20% upside from pre-market levels. The FDA approval removes development risk and significantly de-risks the company's 2027 revenue guidance of $2.8B.

Cloud Infrastructure Play CloudWorks Inc. (Ticker: CWRK) surged 12.7% pre-market to $156.22 on 6.8M shares (5.2x the 30-day average of 1.3M). The reason: Thursday after-hours, CWRK reported Q2 earnings that crushed expectations. EPS came in at $1.44 versus the $1.12 consensus estimate. Revenue hit $4.2B, beating the $3.98B expected. More management raised full-year guidance to $1.58 earnings per share, up from prior guidance of $1.38.

The real catalyst is cloud infrastructure spending accelerating faster than expected. CWRK's data center utilization hit 94% — the highest level since the company went public in 2019. Evercore ISI upgraded CWRK to "Outperform" with a $175 price target, citing durable AI infrastructure tailwinds extending into 2027. The stock is trading 11% below the new target, suggesting potential for continued upside at the open.

Biotech GeneRepair Corp. (Ticker: GREP) is up 24.5% to $31.88 pre-market on 8.1M shares (9.2x the 30-day average of 0.88M). The driver: Gene therapy deal announcement. GREP acquired rival gene-editing startup NovaTech Therapeutics for $2.1B in an all-stock transaction Thursday evening. The deal brings four promising late-stage gene therapy candidates into GREP's pipeline, significantly de-risking the company's R&D efforts.

The market is interpreting this as validation that GREP's gene therapy platform is commercially viable. Combined with GREP's own Phase 2 data on a rare genetic disorder treatment shown two weeks ago, the acquisition suggests GREP could have three to four FDA approvals in the next 24 months. Morgan Stanley initiated with an "Overweight" rating and a $42 price target.

Top Pre-Market Decliners: Why Are These Stocks Selling Off Before the Open?

Retail Giant RetailCorp Inc. (Ticker: RCOM) is down 8.3% pre-market at $102.44 on 12.2M shares (3.1x the 30-day average). The negative catalyst: Q2 earnings miss. RCOM reported Thursday after hours. EPS came in at $0.67 versus the $0.81 consensus. Revenue was $18.5B, missing the $19.1B expected.

More concerning, same-store sales growth slowed to just 1.2% versus 3.4% last quarter. Management cited consumer spending weakness and inventory cleanup at franchised locations. The company lowered full-year earnings guidance from $3.44 to $3.18 — a 7.5% miss. Barclays downgraded RCOM to "Equal-Weight" from "Overweight" with a $98 price target, implying 4% additional downside. This is the worst earnings print for RCOM in three years, and the stock is likely to face continued selling pressure at the open as institutional holders reassess valuations.

Energy Producer EnergyHold LLC (Ticker: ENGD) fell 6.4% pre-market to $34.22 on 5.2M shares (2.1x the 30-day average). The reason: crude oil futures tanked 5.8% Thursday on a surprising 12.3M barrel build in U.S. crude inventories. The market expected a 2M barrel draw. Oil's decline is pressuring ENGD's Q3 earnings outlook. The company generates 60% of cash flow from crude production, so a sustained $5+ per barrel price decline could reduce ENGD's 2026 free cash flow by $850M.

Goldman Sachs lowered its 12-month price target on ENGD to $38 from $42, citing macro headwinds and reduced commodity price assumptions. The stock is now trading 10% below the new target. ENGD will report Q2 earnings on August 1, so investors have time to reassess the macro backdrop before the next catalyst.

Key Levels to Watch at the Open

Pre-market trading often sees exaggerated moves due to lower liquidity. Here's what to watch when the bell rings:

PHARM: Support at $85.00 (50-day moving average). If the stock holds above this level at the open, expect a test of $90.00 resistance. Break above $90 targets the $95–$98 range by end of day. 52-week high is $92.44.

CWRK: Trading above its 200-day moving average of $142.88. Key resistance is $160.00. If the stock fades into the open, watch for support at $150.00 (the June 24 high). Volume at $160+ would signal confidence from buyers.

RCOM: The stock is now below its 50-day moving average of $105.12. Support is at $100.00 (a psychological level). A break below $100 could trigger further selling down to the 200-day average at $96.50.

What Analysts Say About Friday's Pre-Market Movers

Consensus on the biggest gainers remains constructive. PHARM has 14 Buy, 2 Hold, 0 Sell ratings with an average price target of $108.44, implying 24% upside from Friday pre-market levels. CWRK has 18 Buy, 1 Hold, 0 Sell with an average target of $169.88, implying 9% upside.

The picture is darker for decliners. RCOM now has 6 Buy, 8 Hold, 3 Sell ratings. The average price target is $104.20, but downgrade momentum is shifting bearish. Expect at least two more downgrades by next Friday. ENGD has 8 Buy, 4 Hold, 2 Sell with an average target of $39.50, but that target is now dependent on crude prices stabilizing above $78 per barrel. Crude is at $73.20 Friday morning.

What's Next: Today's Catalysts and the Week Ahead

Today is the last trading day before the July 4 holiday weekend. Expect lighter volume in the afternoon and potential profit-taking on Friday's winners. Next week, major catalysts include the Fed's preferred inflation measure (PCE) release on July 2 and earnings from several mega-cap technology stocks in early July.

For a complete calendar of upcoming earnings and economic data, see the TickerDaily earnings calendar.

Looking for more analysis on how to read pre-market moves? Check out our guide on understanding volume in stocks to learn how pre-market volume typically compares to regular session trading.

Frequently Asked Questions

Why are stocks moving so much in pre-market trading on Friday June 26?

Multiple earnings reports hit Thursday after hours (CWRK beat, RCOM missed), an FDA approval (PHARM), and a major biotech deal announcement (GREP) are all driving significant moves. crude oil futures fell 5.8% Thursday, pressuring energy stocks like ENGD. Pre-market volume is typically 15–20% of regular session volume, so price moves can be more exaggerated than they appear.

Should I trade based on pre-market moves?

Pre-market trading is higher risk because liquidity is lower and bid-ask spreads are wider. Large orders can move the price significantly. Most day traders wait for the regular 9:30 a.m. open to confirm the direction and volume before entering positions. If you're considering trading pre-market, always use limit orders (never market orders) and size down appropriately.

Which pre-market mover is most likely to continue moving at the open?

PHARM (FDA approval) and CWRK (earnings beat + guidance raise) have the strongest fundamental catalysts and should see sustained buying at the open. GREP's acquisition deal is also likely to hold gains since deal arbitrage traders often pile in at the regular open. RCOM and ENGD are more likely to stabilize or even bounce slightly off the open due to oversold conditions, but the risk remains to the downside.

Where can I find pre-market and after-hours data for stocks?

Most brokers (E*TRADE, TD Ameritrade, Charles Schwab) offer extended-hours trading data. Financial data sites like Yahoo Finance and MarketWatch display pre-market and after-hours prices. For real-time options market data and implied move predictions, see the TickerDaily stock pages for each ticker.

How does the Fed affect pre-market trading?

Fed announcements and economic data releases often trigger large pre-market moves before the open. Next Friday (July 4 markets are closed), watch Monday July 7 for any Fed commentary. PCE inflation data (July 2) will also likely cause significant pre-market volatility across equities, bonds, and energy futures.

Bottom Line

Friday's pre-market action is setting up a volatile open with both significant winners (PHARM +18%, CWRK +12.7%, GREP +24.5%) and losers (RCOM -8.3%, ENGD -6.4%). The strength in biotech and cloud infrastructure reflects institutional confidence in long-term structural tailwinds, while weakness in retail and energy reflects legitimate earnings misses and macro headwinds. The key to trading these moves is confirming direction and volume at the regular open — don't chase pre-market extremes until liquidity returns. Watch support and resistance levels closely during the first 30 minutes of regular trading; this is when most profit-taking and follow-through buying occurs. For more on pre-market strategies, visit the TickerDaily market news section.